Performance evaluation of multiquadrant DC drive using fuzzy- genetic approach

This paper presents the simulation of multiquadrant DC drive using Fuzzy Logic Control (FLC) for various operating conditions. Genetic Algorithm (GA) has been used in the design of membership functions and rule sets for eliminating the need of human input in the design loop. Performance analysis is performed through mathematical simulation for the stable operation of the drive. Simulated results validate the proposed control techniqu

Role of different Juices in the Management of Osteoarthritis, Rheumatoid Arthritis and Backache - A Review

Skeletal system is a very important system of living body. If any malformation occurs it leads to severe problems which are highly intolerable by an individual. Some of the diseases comes under this are osteoarthritis, rheumatoid arthritis, backache, etc. Management of such diseases is now based on diagnosis, but still it is complicated to treat and associated causes are difficult to find out in many cases. Mainly diet plays a major and important role in prevention of skeletal disorders, under diet regimen different combination of fruit and vegetable juices plays a vital role in management of diseases. Modification in combination of juices and knowledge of their chemical constituent helps in management of skeletal disorder. Due to deficiency of mineral, vitamin or other necessary component is find out, we can use the natural supplement in the form of juices which are rich in minerals, vitamins and get easily digest and minimize the risk of the disease and provide soothing results. Juices of spinach, broccoli, apple, parsley, cherry, blueberry, ginger root, carrot, lettuce, kale, turnip, etc. plays an important role in management of different types of skeletal disorders. By proper knowledge of chemical constituent of fruits and vegetable we may minimize the risk of diseases associated with skeletal system and helps the sufferer up to a better extent

Modeling and Control of PV Emulator with Different Controllers and Transient Load Conditions

To keep up with the pace of renewable energy, PV Emulators are encouraged during the design and installation stages. Short circuit current, maximum power point and open circuit voltage are required to analyze the complete characteristic plot of PV panel.This paper focuses on the modeling and control of PV Emulators, as well as the comparison of the results obtained by implementing P,PI, PID and FOPID as conventional controllers with AI-based PSOPI, PSOPID and ANFIS controllers. This work will aid in minimizing time, cost and on-site constraints, allowing timely installation of PV panels after covid. Another distinguishing feature of this paper is the comparative analysis of designed models with various control strategies and their associated performance indices over complete range of PV characteristics

A REVIEW ON CLEANING VALIDATION IN PHARMACEUTICAL INDUSTRY

In pharmaceutical industry there are some possibilities of contamination and cross-contamination because of improper cleaning of equipment, apparatus, processing area or the starting material, this can lead to severe hazards, therefore in pharmaceutical industry we can’t afford any contamination as well as cross contamination. This can be minimized by proper cleaning of equipment, apparatus as well as the processing area. TheIndustry wants to achieve these main goals with the help of GMP. This review focused on the different types of cleaning process adapted by pharmaceutical industry, how the process of cleaning validation is done. In the cleaning validation different critical parameter, factor, material and critical process are monitored and validated so that the cleaning consistency can be achieved and documented accordingly. Keywords: Cleaning validation, contamination, clean in place, clean out of place, swab sampling, worst cas

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention